CG Oncology, Inc. SEC Filings

Brian Guan-Chyun Liu, a director of CG Oncology, Inc. (CGON), reported a purchase of 1,515,151 shares of the company's common stock on 09/11/2025 at a price of $33 per share. The filing shows the shares were acquired (transaction code P) and that 1,515,151 shares were beneficially owned following the transaction. Ownership is reported as indirect through Seven Fleet Partners LP; Liu disclaims direct beneficial ownership except to the extent of any pecuniary interest. The form is signed on 09/12/2025.

James J. Mulay, a director of CG Oncology, Inc. (CGON), exercised a fully vested director stock option to buy 27,015 shares at an exercise price of $0.60 on 09/05/2025. The same day he sold a total of 27,015 common shares under a Rule 10b5-1 trading plan adopted June 6, 2025, at weighted-average prices ranging across four blocks: $30.47, $31.42, $32.64, and $33.22. Following these transactions the reporting person reports 0 shares beneficially owned. Sales were effected pursuant to the 10b5-1 plan and the option was fully vested.

CG Oncology, Inc. (CGON) filing a Form 144 to report a proposed sale of common stock. The notice shows 27,015 shares to be sold through Morgan Stanley Smith Barney LLC on 09/05/2025 on NASDAQ with an aggregate market value of $835,844.10 and 76,247,581 shares outstanding. The securities were acquired on 09/05/2025 by exercise of stock options from the issuer, paid in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

CG Oncology director Hong Fang Song (filing signed by attorney-in-fact) reported multiple sales of common stock on 09/03/2025 under a written plan. The Form 4 shows discrete dispositions of 69,695, 30,105, 100, 100 and 613,928 shares, totaling 713,928 shares sold. Two groups are identified as record holders: Charming Jade Limited and Unique Diamond Investments Limited, and Ms. Song discloses indirect beneficial ownership through a chain of entities she ultimately owns. The filing notes weighted average price ranges for portions of the sales and indicates the transactions were made pursuant to a Rule 10b5-1 plan.

Leonard E. Post, a director of CG Oncology, Inc. (CGON), reported transactions on Form 4 dated 09/04/2025 reflecting activity on 09/03/2025. The filing shows purchase and sale activity plus option holdings. Mr. Post acquired 1,000 shares of common stock at $0.60 per share and simultaneously sold 1,000 shares under a Rule 10b5-1 plan at $28.00 per share. The director holds a fully vested stock option exercisable at $0.60 covering 1,000 shares and, following the reported transactions, beneficially owns 125,077 shares directly. The sale was executed pursuant to a 10b5-1 trading plan adopted on September 6, 2024.

CG Oncology (CGON) Form 144: The filer notifies a proposed sale of 100,000 shares of common stock through Merrill Lynch on NASDAQ with an approximate sale date of 09/03/2025. The aggregate market value is reported as $2,746,000.00 and the company reports 76,247,581 shares outstanding, implying the filing relates to a transaction representing a known, disclosed portion of outstanding equity.

The securities were acquired on 01/25/2024 in a private placement from the Company and paid in cash the same day. No securities were reported sold by the person in the past three months. The filing includes the standard signature representation that the seller is not aware of undisclosed material adverse information.

CG Oncology, Inc. (CGON) reported a Form 144 notice indicating a proposed sale of 1,000 common shares by a person exercising stock options on 09/03/2025. The shares were acquired and paid for in cash on the same date through exercise of stock options from the issuer. The proposed sale lists Morgan Stanley Smith Barney LLC as the broker and an aggregate market value of $27,460 based on the filing. The filer also disclosed two prior 10b5-1 plan sales on 07/17/2025 totaling 2,000 shares with gross proceeds of $56,000. The form includes the standard representation that the seller is unaware of undisclosed material adverse information.